You are here

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Last updated on October 4, 2018

FOR MORE INFORMATION
Study Location
The Canberra Hospital
Garran, Australian Capital Territory, 2605 Australia
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Meningococcal Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
12-14 months
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion
of the investigator, can and will comply with the requirements of the protocol.

- A male or female between, and including, 12 and 14 months of age at the time of the
first vaccination.

- Written informed consent obtained from the parent(s)/LAR(s) of the subject.

- Healthy subjects as established by medical history and clinical examination before
entering into the study.

- Vaccination records showing the completion of the full primary vaccination schedule
with Prevenar 13 and Diphtheria, Tetanus and Pertussis (DTP) containing vaccine
according to local recommendations at least 5 months before the study entry.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Child in care.

- Use of any investigational or non-registered product (drug or vaccine) other than the
study vaccines within 30 days preceding the first dose of study vaccine or planned use
during the study period.

- Chronic administration (defined as more than 14 days in total) of immunosuppressants
or other immune-modifying drugs within six months prior to the first vaccine dose. For
corticosteroids, this will mean prednisone 0.5 mg/kg/day, or equivalent. Inhaled and
topical steroids are allowed.

- Planned administration/administration of a vaccine not foreseen by the study protocol
within the period starting 30 days before and ending 30 days after the dose of
vaccines, with the exception of a licensed inactivated influenza vaccine. Measles,
Mumps Rubella (MMR) vaccine or Measles Mumps Rubella and Varicella (MMRV) vaccine can
be co-administered with MenACWY-TT and/or Prevenar 13. A DTPa containing vaccine can
be administered after the last blood sampling (at Visit 2 or 4 depending on the
group).

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational vaccine/product (pharmaceutical product or device).

- Previous vaccination against Neisseria meningitidis.

- Previous booster vaccination against Streptococcus pneumoniae.

- Previous booster vaccination against Corynebacterium diphtheriae, Clostridium tetani
and Bordetella pertussis.

- History of meningococcal disease.

- Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital
or secondary), including human immunodeficiency virus (HIV) infection, based on
medical history and physical examination (no laboratory testing required)*

- Note: With the exception of HIV rapid testing which will be done for subjects in
South Africa.

- Family history of congenital or hereditary immunodeficiency.

- History of any reaction or hypersensitivity, including to diphtheria toxoid, likely to
be exacerbated by any component of the vaccines.

- Major congenital defects or serious chronic illness.

- History of any neurological disorders or seizures, including Guillain-Barré syndrome
(GBS). History of a simple, single febrile seizure is permitted.

- Acute disease and/or fever at the time of enrollment.

- Administration of immunoglobulins and/or any blood products within the 3 months
preceding the first dose of study vaccine or planned administration during the study
period.

NCT01939158
Pfizer
Active, not recruiting
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13?Vaccine
A Phase III, Randomised, Open, Controlled, Multicentre, Primary Vaccination Study To Evaluate The Immunogenicity And Persistence Of 1 And 2 Doses Of Meningococcal Conjugate Vaccine MenACWY-TT In Toddlers (After 1 Month And Up To 5 Years) And To Demonstrate Non-inferiority Of Co-administration Of MenACWY-TT And 13-valent Pneumococcal Conjugate Vaccine Prevenar 13(Registered) Versus Separate Administration Of The 2 Vaccines
The purpose of this study is to compare the immediate and long term (up to 5 years) immunogenicity and safety of GSK Biologicals' MenACWY-TT vaccine when given as a single dose or as 2 doses to toddlers aged 12 to 14 months. Also, this study will also assess if co-administration of GSK Biologicals' MenACWY-TT with the booster dose of Pfizer's Prevenar 13 adversely impacts the immunogenicity of either of the vaccines.
The Medicines Control Council (MCC) authorities requested that subjects be screened for HIV testing prior to study enrolment in South Africa to ensure that only HIV negative participants are enrolled. As such, HIV rapid test was added at Visit 1 only for subjects in South Africa. Subjects previously screened HIV positive will be excluded.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Infections, Meningococcal
  • Biological: Meningococcal vaccine GSK134612
    1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
  • Biological: Prevenar 13?
    1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
  • Experimental: ACWY1d group
    Subjects will receive 1 dose of the MenACWY-TT vaccine
    Intervention: Biological: Meningococcal vaccine GSK134612
  • Experimental: ACWY2d group
    Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart
    Intervention: Biological: Meningococcal vaccine GSK134612
  • Experimental: Co-ad group
    Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13?
    Interventions:
    • Biological: Meningococcal vaccine GSK134612
    • Biological: Prevenar 13?
  • Active Comparator: PCV-13 group
    Subjects will receive 1 dose of Prevenar 13? and 1 dose of the MenACWY-TT vaccine 2 months later
    Interventions:
    • Biological: Meningococcal vaccine GSK134612
    • Biological: Prevenar 13?
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
804
February 12, 2020
February 12, 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female between, and including, 12 and 14 months of age at the time of the first vaccination.
  • Written informed consent obtained from the parent(s)/LAR(s) of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Vaccination records showing the completion of the full primary vaccination schedule with Prevenar 13 and Diphtheria, Tetanus and Pertussis (DTP) containing vaccine according to local recommendations at least 5 months before the study entry.

Exclusion Criteria:

  • Child in care.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine or planned use during the study period.
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after the dose of vaccines, with the exception of a licensed inactivated influenza vaccine. Measles, Mumps Rubella (MMR) vaccine or Measles Mumps Rubella and Varicella (MMRV) vaccine can be co-administered with MenACWY-TT and/or Prevenar 13. A DTPa containing vaccine can be administered after the last blood sampling (at Visit 2 or 4 depending on the group).
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
  • Previous vaccination against Neisseria meningitidis.
  • Previous booster vaccination against Streptococcus pneumoniae.
  • Previous booster vaccination against Corynebacterium diphtheriae, Clostridium tetani and Bordetella pertussis.
  • History of meningococcal disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination (no laboratory testing required)*

    • Note: With the exception of HIV rapid testing which will be done for subjects in South Africa.
  • Family history of congenital or hereditary immunodeficiency.
  • History of any reaction or hypersensitivity, including to diphtheria toxoid, likely to be exacerbated by any component of the vaccines.
  • Major congenital defects or serious chronic illness.
  • History of any neurological disorders or seizures, including Guillain-Barré syndrome (GBS). History of a simple, single febrile seizure is permitted.
  • Acute disease and/or fever at the time of enrollment.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
Sexes Eligible for Study: All
12 Months to 14 Months   (Child)
Yes
Contact information is only displayed when the study is recruiting subjects
Australia,   Canada,   Czechia,   Panama,   South Africa,   Turkey
Czech Republic
 
NCT01939158
MENACWY-TT-104
C0921003 ( Other Identifier: Alias Study Number )
2013-001083-28 ( EudraCT Number )
116892 ( Other Identifier: Alias Study Number )
Not Provided
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Yes
Plan Description:

Information relating to our policy on data sharing and the process for requesting data can be found at the following link:

http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...

URL: http://
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now